Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Biohaven Ltd. logoBiohaven Ltd.

BHVN · the NYSE · USD · Market cap $2.0B · 274 employees

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

FAIL · Does not pass the screen
12.39 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price12.39 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 2.87)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $9.00 to $25.80, base estimate $23.00 (screen dated 2026-11-20).

Current read
Markup ?
Undervalued · screened 2026-11-20
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 2.87, read 2026-11-19
  • Ethical does not pass the values gate
Price12.39 USD
Fair value23.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-10-27Read Markup11.75+5.4% to today ✓Distribution gives way to Markup after a 17% slide in 4 weeks
2026-10-02Read Distribution14.22-12.9% to today ✓Markdown gives way to Distribution with volume flow in agreement
2026-08-23Read Markdown14.39-13.9% to today ✓Markup gives way to Markdown after a 28% rise in 7 weeks
2026-07-02Read Markup11.28+9.8% to today ✓First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Biohaven Ltd. holds its Markup at $12.39. Consolidating, no directional conviction, held for 16 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 16 days
Price at the screen$12.39
ValuationN/A trailing · -8.64 forward price to earnings
Values screenFAIL · score 70.0
Beta3.14
The Workings

Five Screens: BHVN's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 63.04% Below 33% Fail
Interest-bearing cash 19.75% Below 33% Pass
Receivables 50.94% Below 49% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Biohaven's business is in a permissible area, but its interest-bearing debt is about 63% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when BHVN's ethical verdict changes

Today BHVN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 46% discount to our $23.00 fair value.

Method.

9.00Conservative23.00Base case25.80Growth case 12.39Price

USD, 2026-11-20 screen. A 46.1% under base.

The Street's Range
9.00Street low 23.00Street average 48.00Street high 12.39Price

Street: 15 covering, consensus Buy. Average target +86%.

Chart
The Business, in Plain Words

Biotech Pipeline Lacks Numbers and Ethical Clarity

Imagine betting on a lab that burns cash on every trial with no profits in sight. Biohaven develops treatments for immunology and oncology yet posts zero margins and returns on equity of minus three hundred thirty three per cent. The forward multiple sits at minus seven point nine times while the share price of fifteen dollars forty four sits below our calculated fair value.

Analysts like the story and set a median target near twenty dollars. We pass outright. The ethical screen returns insufficient data because basic financial ratios are missing, so no verdict on governance or long term impact is possible.

Without those details the apparent margin of safety stays unusable. Funding cycles in early stage biotech add further opacity that no consensus rating can fix. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-8.6x
EPS, trailing-3.76
EPS, forward-1.53
Profit margin0.0%currently unprofitable
FCF yield-11.47%
Current ratio3.05comfortably covers its short-term bills
Beta3.14much more volatile than the market
Short interest, float0.13%
52-week range8.03 - 18.24
Market cap$2.0B
Employees274

BHVN-specific watchpoints · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $12.90 -6.7% Entry 13
2026-11-17 Markup $13.82 -9.3% Entry 12
2026-11-10 Markup $15.23 -1.2% Entry 11

Since the last review it saw its composite score rise.

2026-11-03 Markup $15.42 +31.2% Entry 10
2026-10-27 Markup · changed $11.75 +2.8% Entry 9

The framework has shifted from distribution to markup since the last review.

2026-10-20 Distribution $11.43 -5.4% Entry 8
2026-10-13 Distribution $12.08 -15.0% Entry 7
2026-10-02 Distribution · changed $14.22 -1.2% Entry 6

The framework has shifted from markdown to distribution since the last review. Since the last review it saw its composite score rise.

2026-08-23 Markdown · changed $14.39 -6.8% Entry 5

The framework has shifted from markup to markdown since the last review.

2026-07-23 Markup $15.44 +36.9% Entry 4

Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on BHVN

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in BHVN's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $9.08 +20.2% · $1,202 +20.2%
2 months $9.17 +19.0% · $1,190 +19.0%
3 months $9.91 +10.1% · $1,101 +10.1%
6 months $11.44 -4.6% · $954 -4.6%
1 year $16.79 -35.0% · $650 -35.0%
2 years $35.06 -68.9% · $311 -68.9%
3 years $23.85 -54.3% · $457 -54.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever BHVN does next, these words stay.

Biohaven Ltd. · BHVN · Markup · $12.39
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.